All articles tagged with #rapamycin
A Cell-published theory argues that reproductive tissues, especially the ovary, help drive systemic resilience and aging, suggesting women’s reproductive history may shape health span and that aging research should center female physiology; early mouse data show rapamycin can delay ovarian aging, with human trials anticipated, signaling a shift toward sex-specific approaches in longevity medicine.
Pet owners are spending billions on experimental anti‑aging treatments for dogs and cats—ranging from rapamycin and peptide injections to red‑light therapy and supplements—driven by human longevity trends. While some owners report noticeable costs (roughly hundreds of dollars per month) and enroll pets in scientific trials, there is still limited scientific proof of effectiveness for pets; the movement illustrates a broader DIY health surge in the $165 billion pet‑care market.
A single dose of rapamycin given to adult mice exposed to maternal inflammation reverses most autism-like brain and behavioral changes within about two hours by rapidly normalizing neural activity and network patterns, likely through dampening mTOR signaling and restoring excitation–inhibition balance. The effects are fast but temporary and do not repair underlying structural brain changes; long-term use carries toxicity risks, but the findings point to new targets such as sensory circuit modulation rather than rapamycin itself.
Maternal inflammation during pregnancy induces lasting autism-like brain changes in mice; a single dose of rapamycin quickly normalized neuronal activity, reduced seizures, and improved sensory processing and repetitive behaviors within about two hours. The effects were temporary and rapamycin is not a practical human treatment, but the study highlights the brain's functional adaptability and points to new targets in mTOR signaling and circuit modulation.
In a mouse model of maternal immune activation, a single dose of rapamycin rapidly normalized neuronal activity, reduced seizure susceptibility, improved brain network connectivity, and lessened autism-like behaviors within about two hours. Since this window is too short for structural brain changes, the results reveal adult functional plasticity and point to therapeutic targets in mTOR signaling, neuronal excitation balance, and sensory circuits—though rapamycin itself is not suitable for humans due to toxicity and tolerance, guiding safer circuit-focused approaches.
Silicon Valley’s longevity movement gets a reality check as Bryan Johnson halted Rapamycin after years of self-testing, highlighting the gap between hype and proven science: there’s no clinical evidence that any current intervention extends human life, and much of the field rests on self-reported data and individualized tests rather than large-scale trials, even as tech culture pushes rapid experimentation and interest in aging-related drugs like metformin and GLP-1 inhibitors continues.
A Washington Post Well+Being study finds that rapamycin, a longevity drug, may blunt the health benefits of exercise, with older adults taking the drug showing less strength and functional gains from training than those on placebo, suggesting off‑label use for lifespan extension could impair muscle adaptation via the mTOR pathway.
Ralph, a beloved family dog, developed dementia and joined the Dog Aging Project, a large study of aging in dogs that aims to illuminate human neurodegenerative diseases. Scientists compare dog and human brains to understand dementia, noting similar structural changes and brain shrinkage. Memory tests and MRI scans underscored Ralph’s cognitive decline, while a pilot rapamycin trial suggested reduced brain inflammation in treated dogs. After Ralph’s death, researchers continued posthumous brain analysis, reinforcing the potential of canine aging research to inform human health. The Rowe family finds purpose in Ralph’s contribution to science and encourages keeping dogs mentally and physically active for brain health.
The Dog Aging Project tracks 50,000+ dogs to study aging and dementia, linking lifestyle factors to disease risk and showing that canine brain aging shares features with human dementia. The effort includes diets, exercise, blood work, and brain MRIs, plus brain donations for analysis. Early findings suggest dogs living with others and remaining active have fewer diseases, and a pilot rapamycin study showed reduced brain inflammation in some dogs, prompting larger NIH-funded trials and the push to develop dog-focused longevity therapies.
A new study finds that Rapamycin, originally an immunosuppressant, extends lifespan in eight vertebrate species as effectively as dietary restriction, while Metformin shows no clear benefit, highlighting Rapamycin's potential in aging research.
A meta-analysis suggests that rapamycin may extend lifespan in animals similarly to dietary restrictions, unlike metformin, but human trials are needed to confirm its effects and safety for longevity in people.
Scientists found that rapamycin, a drug that mimics the effects of dieting, can extend lifespan in animals almost as effectively as actual calorie restriction, whereas metformin does not show the same benefit. While promising, more research is needed to confirm safety and effectiveness in humans, and current evidence is primarily from animal studies.
A recent study shows that rapamycin extends lifespan almost as effectively as calorie restriction in animals, making it a promising anti-aging drug, while metformin shows less consistent benefits. However, more research is needed, especially in humans, to confirm safety and efficacy.
A new study shows that rapamycin extends lifespan almost as effectively as calorie restriction in animals, unlike metformin, which shows no clear benefit. While promising, more research is needed to confirm safety and efficacy in humans, and current evidence is primarily from animal studies.
Scientists in Europe found that a cocktail of two cancer drugs, rapamycin and trametinib, extended mice lifespans by about 30%, improved health markers, and delayed age-related diseases, suggesting potential for human anti-aging therapies, though more research is needed.